Gadobenic acid: Difference between revisions

	WikiDoc Resources for Gadobenic acid
Articles
Most recent articles on Gadobenic acid Most cited articles on Gadobenic acid Review articles on Gadobenic acid Articles on Gadobenic acid in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Gadobenic acid Images of Gadobenic acid Photos of Gadobenic acid Podcasts & MP3s on Gadobenic acid Videos on Gadobenic acid
Evidence Based Medicine
Cochrane Collaboration on Gadobenic acid Bandolier on Gadobenic acid TRIP on Gadobenic acid
Clinical Trials
Ongoing Trials on Gadobenic acid at Clinical Trials.gov Trial results on Gadobenic acid Clinical Trials on Gadobenic acid at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Gadobenic acid NICE Guidance on Gadobenic acid NHS PRODIGY Guidance FDA on Gadobenic acid CDC on Gadobenic acid
Books
Books on Gadobenic acid
News
Gadobenic acid in the news Be alerted to news on Gadobenic acid News trends on Gadobenic acid
Commentary
Blogs on Gadobenic acid
Definitions
Definitions of Gadobenic acid
Patient Resources / Community
Patient resources on Gadobenic acid Discussion groups on Gadobenic acid Patient Handouts on Gadobenic acid Directions to Hospitals Treating Gadobenic acid Risk calculators and risk factors for Gadobenic acid
Healthcare Provider Resources
Symptoms of Gadobenic acid Causes & Risk Factors for Gadobenic acid Diagnostic studies for Gadobenic acid Treatment of Gadobenic acid
Continuing Medical Education (CME)
CME Programs on Gadobenic acid
International
Gadobenic acid en Espanol Gadobenic acid en Francais
Business
Gadobenic acid in the Marketplace Patents on Gadobenic acid
Experimental / Informatics
List of terms related to Gadobenic acid

Gadobenic acid
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	V08CA08 (WHO) ;
Identifiers
	IUPAC name 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-;
CAS Number	113662-23-0 ;
PubChem CID	105124;
DrugBank	DB00996 ;
ChemSpider	94843 ;
UNII	15G12L5X8K;
KEGG	D08018 ;
ChEMBL	ChEMBL1200571 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C22H28GdN3O11
Molar mass	667.72 g/mol
3D model (JSmol)	Interactive image;
	SMILES [H+].[H+].[Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)C(C([O-])=O)COCc1ccccc1;
	InChI InChI=1S/C22H31N3O11.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);/q;+3/p-3 ; Key:MXZROTBGJUUXID-UHFFFAOYSA-K ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 16:23, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Gadobenic acid (tradename MultiHance) is a complex of gadolinium with the ligand BOPTA. In the form of the diglumine salt it functions as a gadolinium-based MRI contrast medium, under the trade name gadobenate dimeglumine.

BOPTA is a derivative of DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–CH₂C₆H₅. Thus gadobenic acid is closely related to gadopentetic acid. BOPTA itself was first synthesized in 1995. ^[1] In the "gadobenate" ion gadolinium ion is 9-coordinate with BOPTA acting as an 8-coordinating ligand. The ninth position is occupied by a water molecule, which exchanges rapidly with water molecules in the immediate vicinity of the strongly paramagnetic complex, providing a mechanism for MRI contrast enhancement. ¹³⁹La NMR studies on the diamagnetic La-BOPTA²⁻ complex suggest that the Gd complex maintains in solution the same kind of coordination as found, by X-ray crystallography, in the solid state for Gd-BOPTA disodium salt.^[1]

↑ ^1.0 ^1.1 Uggeri, F.; Aime, S., Anelli, P.L., Botta, M., Brocchetta, M., De Haën, C., Ermondi, G., Grandi, M., Paoli, P. (1995). "Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)]gadolinate(2-) in a mixture with its enantiomer". Inorg. Chem. 34 (3): 633–642. doi:10.1021/ic00107a017.

Template:Contrast media

[synth-1] 1.0 ^1.1 Uggeri, F.; Aime, S., Anelli, P.L., Botta, M., Brocchetta, M., De Haën, C., Ermondi, G., Grandi, M., Paoli, P. (1995). "Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)]gadolinate(2-) in a mixture with its enantiomer". Inorg. Chem. 34 (3): 633–642. doi:10.1021/ic00107a017.

[1]

@@ Line 4: / Line 4: @@
 | IUPAC_name = 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-
 | <!-- image = Gadobenic acid.png -->
-| image = Structure of Gadobenic acid.png
+| image =Gadobenic acid.png
 <!--Clinical data-->
 | tradename =
@@ Line 55: / Line 55: @@
 }}
 __NOTOC__
 {{SI}}
 {{CMG}}
 ==Overview==
 '''Gadobenic acid''' (tradename MultiHance) is a complex of [[gadolinium]] with the ligand BOPTA. In the form of the diglumine salt it functions as a [[gadolinium-based MRI contrast medium]], under the trade name ''gadobenate dimeglumine''.
@@ Line 81: / Line 78: @@
 {{Contrast media}}
-[[Category:MRI contrast agents]]
-[[Category:Gadolinium compounds]]
 [[Category:Drug]]

Gadobenic acid: Difference between revisions

Latest revision as of 16:23, 20 August 2015

Overview

Navigation menu

Search